Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy

Launched by HUNAN CANCER HOSPITAL · Aug 31, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how nutrition can help improve the health and quality of life of patients with esophageal and gastric cancer who are undergoing chemotherapy. The researchers want to see if providing nutritional counseling or support can make a difference in how these patients feel and how well they are able to manage their cancer treatment.

To participate in this study, individuals need to be between 18 and 75 years old and have been diagnosed with esophageal or gastric cancer. They should be able to continue with chemotherapy for at least three more cycles and have certain blood test results that show they are stable enough to participate. Participants will be randomly assigned to either receive nutritional counseling or nutritional support therapy. This trial is not yet recruiting, but it aims to help improve the understanding of how nutrition affects cancer care, which could lead to better support for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Esophageal or gastric cancer confirmed by histology or cytology;
• • Age 18-75 years old, gender unlimited;
• • Blood routine: hemoglobin ≥90g/L, absolute neutrophil count (ANC) ≥1.5×109/L, platelets ≥100×109/L; (2) Liver and kidney function: alanine transaminase（ALT）, glutamic-oxalacetic transaminease（AST）≤2.5 times the normal upper limit (with liver metastasis ≤5 times the normal upper limit); ALP≤2.5 times the normal upper limit (≤5 times the normal upper limit for patients with liver or bone metastasis); Serum total bilirubin (TBIL) was less than 1.5 times the normal upper limit. Serum creatinine (SCr) \< 1.5 times the upper limit of normal; ③ Blood biochemistry: Serum albumin (ALB) ≥30g/L;
• • Predicted survival of more than 3 months; It is planned to continue chemotherapy for \>3 cycles in the hospital or outpatient department
• • All patients participated in this study voluntarily and signed informed consent.
• Exclusion Criteria:
• • Other tumors, including pancreatic cancer, liver cancer and other solid digestive tract tumors, colon cancer, rectal cancer and other tubular lower digestive tract tumors;
• • Have serious heart, lung and brain diseases; Complicated with chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency, etc.
• • Fever associated with infection; Have difficult-to-control diabetes or other metabolic diseases;
• • Patients with unstable vital signs and multiple organ failure;
• • The patient has poor cognitive ability and is unable to answer questions or fill out questionnaires.
• • The investigator believes that the subjects have a history of other serious systemic diseases or are not suitable for participating in this clinical study for other reasons